- Ongoing, recruitingTherapeutic confirmatory (Phase III)
J2A-MC-GZGW: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared with Placebo in Adult Participants with Type 2 Diabetes and Inadequate Glycemic Control with Insulin Glargine, with or without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)
This study is looking into a new daily tablet, orforglipron, for adults with type 2 diabetes. We want to see if it's better than a dummy pill at helping control blood sugar when taken with insulin glargine and other diabetes medicines.
For: Type 2 DiabetesRomania - RecruitingPHASE3
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
This study for children aged 2-17 with kidney disease looks at a medicine called empagliflozin. We want to see if it helps their kidneys and how well their body handles it. Participants take the medicine or a dummy pill for 6 months, then everyone takes the medicine for a year.
For: Chronic Kidney DiseaseUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
This study looks into a new treatment for adults with heart failure. It combines two medicines, vicadrostat and empagliflozin, to see if they can improve heart health in people with a specific type of heart failure. Participants take tablets daily and are closely monitored.
For: Heart FailureUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
This study looks at different treatment combinations for advanced breast cancer, including those that have spread or are hard to remove. Doctors want to see how well these new drug combinations work and if they are safe for patients.
For: Metastatic Breast CancerUnited States · Australia · France - Active not recruitingPHASE2
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
This study looks at a new medicine, vicadrostat, combined with empagliflozin, for adults with chronic kidney disease. Participants will take pills daily for 3 months, with regular checks on their kidney health and general well-being. It aims to see if starting medicines at different times impacts results.
For: Chronic Kidney DiseaseUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
This study investigates if a new drug, vicadrostat, combined with empagliflozin, can help adults with heart failure and a weakened heart pump. Participants will take study medications for up to 3.5 years, alongside their usual care.
For: Heart FailureUnited States · Argentina · Belgium - Ongoing, recruitingTherapeutic use (Phase IV)
A Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Adults With Type 2 Diabetes
This study is looking at how well a new medicine, Tirzepatide, works for adults with type 2 diabetes when they switch from another medicine called Dulaglutide. Researchers want to see if the new medicine helps lower blood sugar and improve other health markers like weight.
For: Type 2 DiabetesRomania · Germany · Belgium - Ongoing, recruitingPhase III and phase IV (Integrated)
Initiation of angiotensin receptor-neprilysin inhibitor (ARNi) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with heart failure with reduced ejection fraction (HFrEF): the INITIATE-HFrEF randomized open-label trial
This study is looking at new ways to treat heart failure where the heart struggles to pump blood effectively. It compares different combinations of existing medicines to see which approach works best and is safest for patients over a six-month period.
For: Heart failure with reduced ejection fractionPortugal - Ongoing, recruitingTherapeutic exploratory (Phase II)
Randomised, open-label and parallel group trial to investigate the effects of oral BI 685509 alone or in combination with empagliflozin on portal hypertension after 8 weeks treatment in patients with clinically significant portal hypertension (CSPH) in compensated cirrhosis
This study looks at new ways to treat high blood pressure in the liver, called portal hypertension, in people with liver scarring (cirrhosis). It tests a new drug, BI 685509, alone or with an existing drug, empagliflozin, to see if they can lower this pressure.
For: Portal hypertensionSpain · Austria · Netherlands - Ongoing, recruitingTherapeutic confirmatory (Phase III)
J2A-MC-GZGS: A Phase 3, Open-Label Study of Once Daily Orforglipron Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)
This study is testing a new medicine, Orforglipron, for adults with type 2 diabetes and who are overweight or obese. It's looking at how well it works compared to an insulin called Glargine to protect against heart problems.
For: Obesity · Chronic Kidney disease · Type 2 DiabetesGreece · Germany · Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Multicentre, Randomized, Double-blind, Placebo-controlled, phase III study to evaluate the efficacy and safety of Pioglitazone co-administration in patients with type II diabetes with insufficient glycemic control with Metformin and Empagliflozin combination therapy
This study is looking at a new way to treat Type 2 diabetes. It aims to see if adding an extra medication, Pioglitazone, to a common treatment (Metformin and Empagliflozin) helps people manage their blood sugar better. It also checks if this new combination is safe.
For: Type 2 diabetes mellitus (T2DM)Poland - RecruitingPHASE3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study looks at a new medicine, vicadrostat, for people with type 2 diabetes, high blood pressure, and heart disease. It aims to see if taking vicadrostat alongside empagliflozin can help reduce heart problems. Half the participants will get the study medicine, and half will get a dummy pill.
For: Diabetes Mellitus, Type 2 · Hypertension · Cardiovascular DiseasesUnited States · Argentina · Australia - RecruitingPHASE3
Randomised Evaluation of COVID-19 Therapy
The RECOVERY trial looks at treatments for serious lung infections like pneumonia, including COVID-19. It helps doctors find the best ways to help hospitalised patients get better and reduce their risk of dying. Many treatments have been tested, and some have been found to be very helpful.
For: PneumoniaBelgium · Estonia · France - RecruitingPHASE3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
This study looks at a new medicine, BI 690517, combined with empagliflozin, for adults with chronic kidney disease. It aims to see if this combination can help slow down kidney disease progression and protect the heart, for people with and without type 2 diabetes.
For: Kidney Disease, ChronicUnited States · Argentina · Australia